Alnylam Pharmaceuticals Stock News

Received FDA clearance of IND for TSC-100 for the treatment of hematologic malignancies Phase 1 umbrella trial for liquid tumor program to initiate in H1 2022; preliminary data expected in H2 2022 Two INDs for TSC-200 series anticipated by year end Strong balance sheet with cash and cash equivalents of $161.4 million as of December 31, 2021; funds Company into 2024 WALTHAM, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ: TCRX ), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the full year ended December 31, 2021, and outlined key 2022 priorities. "As we had guided throughout 2021, in December we filed two INDs for our liquid tumor program. We also completed construction of our now fully functional 7,000 square-foot GMP manufacturing facility. Both of these steps are instrumental in our transformation to a clinical-stage company," said David Southwell, President and Chief Executive Officer. "We also advanced our growing pipeline of solid tumor candidates and look forward to sharing further details around these programs in the coming months." Recent Corporate Highlights In January 2022, the Company announced that the U.S.

Alnylam Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

DUBLIN--(BUSINESS WIRE)--The "RNA Interference (RNAi) Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com''s offering. The global RNA interference (RNAi) drug delivery market reached a value of US$ 54.74 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 184.98 Billion by 2027, exhibiting a CAGR of 22.5% during 2022-2027. Companies Mentioned Alnylam Pharmaceuticals Inc.

The U.S. Food and Drug Administration ((FDA)) accepted Alnylam Pharmaceuticals (ALNY) supplemental New Drug Application ((sNDA)) seeking approval of OXLUMO (lumasiran) for reducing…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Cowen 42nd Annual Healthcare Conference on Tuesday, March 8, 2022 at 9:50 am ET, being held virtually Barclays Global Healthcare Conference on Tuesday, March 15, 2022 at 8:00 am ET at the Loews Miami Beach Hotel in Miami, Florida A live audio webcast of each presentation will be availa

Novartis AG with ticker code (NVS) now have 5 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 108 and 90 with the average target price sitting at 101.4. Given that the stocks previous close was at 87.94 this now indicates there is a potential upside of 15.3%. The day 50 moving average is 86.37 while the 200 day moving average is 87.38. The market cap for the company is $193,680m. Find out more information at: https://www.novartis.com [stock_market_widget type="chart" template="basic" color="green" assets=NVS" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $223,324m based on the market concensus. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.

Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive Bet

Several Street firms are maintaining bullish views on Alnylam Pharmaceuticals following the biotech Q4 2021 earnings results Thursday.

Alnylam's (ALNY) earnings fall shy of estimates in the fourth quarter of 2021 while revenues beat the same. The company issues 2022 guidance for net product revenues.

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ: ALNY ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 3 2 0 0 Last 30D 0 0 1 0 0 1M Ago 2 1 1 0 0 2M Ago 0 1 0 0 0 3M Ago 2 1 0 0 0 In the last 3 months, 9 analysts have offered 12-month price targets for Alnylam Pharmaceuticals. The company has an average price target of $206.44 with a high of $350.00 and a low of $103.00. Below is a summary of how these 9 analysts rated Alnylam Pharmaceuticals over the past … Full story available on Benzinga.com

CharlieAJA/iStock via Getty Images Alnylam Pharmaceuticals (ALNY +3.0%) is trading higher after the company reported better than expected revenue for Q4 2021, while the bottom line missed…

Alnylam Pharmaceuticals Inc''s (NASDAQ: ALNY ) Q4 product revenues increased 76% Y/Y to $198.5 million , primarily due to the continued global expansion of Onpattro and Givlaari, and sales from a third commercial product, Oxlumo. Collaborations sales increased 18%, primarily due to increased revenue from collaboration agreements with Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) and Novartis AG (NYSE: Full story available on Benzinga.com

Alnylam Pharmaceuticals press release (ALNY): Q4 Non-GAAP EPS of -$1.69 misses by $0.43.Revenue of $258.54M (+58.1% Y/Y) beats by $24.92M.Shares +0.2% PM.Provides 2022 Combined…